| Autor: |
Schmidtmann, I. (Irene), Ageno, W. (Walter), Bauersachs, R.M. (Rupert M.), Becattini, C. (Cecilia), Bernardi, E. (Enrico), Beyer-Westendorf, J. (Jan), Bonacchini, L. (Luca), Brachmann, J. (Johannes), Christ, M. (Michael), Czihal, M. (Michael), Duerschmied, D. (Daniel), Empen, K. (Klaus), Espinola-Klein, C. (Christine), Ficker, J.H. (Joachim H.), Fonseca, C. (Candida), Genth-Zotz, S. (Sabine), Jiménez, D. (David), Harjola, V.P. (Veli-Pekka), Held, M. (Matthias), Iogna-Prat, L. (Lorenzo), Lange, T.J. (Tobias J.), Manolis, A. (Athanasios), Meyer, A. (Andreas), Mustonen, P. (Pirjo), Rauch-Kroehnert, U. (Ursula), Ruiz-Artacho, P. (Pedro), Schellong, S. (Sebastian), Schwaiblmair, M. (Martin), Stahrenberg, R. (Raoul), Westerweel, P.E. (Peter), Wild, P.S. (Philipp S.), Konstantinides, S.V. (Stavros V.), Lankeit, M. (Mareike) |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Popis: |
Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for >_3 months. The primary outcome was symptomatic recurrent venous thromboembolism (VTE) or PE-related death within 3 months of enrolment. An interim analysis was planned after the first 525 patients, with prespecified early termination of the study if the null hypothesis could be rejected at the level of a = 0.004 ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
